INOVIO Form 4 — Humeau Laurent (March 8, 2022)

Summary

Laurent Humeau, Chief Scientific Officer of INOVIO PHARMACEUTICALS, INC. [ INO ], reports that 19,900 Restricted Stock Units settled in Common Stock on 03/08/2022, completing a 59,700-unit award that also vested 19,900 shares on March 8, 2020 and March 8, 2021. The issuer withheld 6,882 shares at $ 3.26 to satisfy the reporting person's tax withholding obligations. Direct holdings after the withholding are 95,605 shares. The form is signed /s/ Laurent Humeau, 03/09/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Humeau Laurent (Last) (First) (Middle) C/O INOVIO PHARMACEUTICALS, INC. 6769 MESA RIDGE RD. (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | Humeau Laurent | (Last) | (First) | (Middle) | C/O INOVIO PHARMACEUTICALS, INC. | 6769 MESA RIDGE RD. | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Scientific Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Scientific Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 03/08/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 03/08/2022 | M | 19,900 | A | (1) | 102,487 | D
Common Stock | 03/08/2022 | F (2) | 6,882 | D | $ 3.26 | 95,605 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Restricted Stock Unit | (1) | 03/08/2022 | M | 19,900 | (1) | (1) | Common Stock | 19,900 | $ 0 (1) | 0 | D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 59,700 restricted stock units is as follows: 19,900 shares vested on March 8, 2020; 19,900 shares vested on March 8, 2021; 19,900 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
2. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
Remarks:
/s/ Laurent Humeau | 03/09/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_INO_4_filed2022-03-09_0001055726-22-000015.xml

Size

17,330 bytes

SHA-256

02b79d61a840d2d3914691201d3c63bcc1d8fa4f0357b128708ba1301b413a4b

Our copy

SEC_INO_4_filed2022-03-09_0001055726-22-000015.xml

Original

www.sec.gov